Skip to main content
SpringerLink
Log in

Biological Response to Acute Leukemia. II. Clinical Effects of Immunomodulation

  • Conference paper
Therapie der akuten Leukämien

  • 25 Accesses

Zusammenfassung

In 1893, Coley reported regressions of human tumors after injections of streptococcal and other bacterial products, and in 1908 Paul Ehrlich suggested that immunologic, antibody-dependent mechanisms could keep aberrant cell clones latent for decades. In 1959, Old revived Coley’s observation showing that BCG prevents transplantable murine tumors. In 1968, Mathé could, with immunotherapy (IT), cure established tumors in animals provided the number of tumor cells was less than 105.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 54.99
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 69.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

Reference

  1. Arends-Merino A, Giscombe R, Ogier C, Reizenstein P, Sjögren A-M, Wasserman J, 1982. Modifying the biologica response in acut myeloid leukemia. II Effect of BCG and leukemia cells on lymphocyte response to mitogens, and on helper and suppressor activity. Cancer Immunol. Immunother. 14:32–35.

    Google Scholar 

  2. Arends-Merino A, Sjögren A-M, Reizenstein P, 1983. Modifying the biological response to acute myeloid leukemia. I. BCG, Allogenic leukemia cells and spontaneous cytotoxicity. Anticancer Research 3:239–242.

    Google Scholar 

  3. Burnet FM, 1970. The concept of immunological surveillance. Prog. Exp. Tumor Res., 13:1.

    PubMed  CAS  Google Scholar 

  4. Büchner Th, Urbanitz D, 1980. Immunotherapie der akuten Leukämie. Der Internist 21:362–366.

    PubMed  Google Scholar 

  5. Coley WB, 1983. Treatment of malignant tumors by repeated inoculation of erypsipelas, with a report of ten cases. Med. Ree., 43:60.

    Google Scholar 

  6. Cuttner J, Holland J, Glidewell O, 1976. Treatment of acute myeloid leukemia with MER. Proc. Am. Assoc. Cancer Res. 16:196.

    Google Scholar 

  7. Cuttner J, Glidewell O, Holland J, 1982. A controlled trial of chemoimmunotherapy of acute myelogenous leukemia with the methanol extraction residue of tubercle bacilli (MER). In: W. Terry, Ed. Immunotherapy of human cancer. Excerpta Medica, N.Y., p. 33–37.

    Google Scholar 

  8. Davis S, Mietlowski W, Rohwedder JJ, Griffin JP, Neshat AA, 1982. Levamisole as an adjuvant to chemotherapy in extensive bronchogenic carcinoma: A veteran administration lung cancer group study. Cancer 50 (4): 646–651.

    Article  PubMed  CAS  Google Scholar 

  9. Galton G A, Peto R, 1978. Immunotherapy of acute myeloid leukemia. Br J Cancer 37:1–14

    Article  Google Scholar 

  10. Hansson M, Beran M, Andersson B, Kiessling R, 1982. Inhibition of in vitro granulopoiesis by autogeneic human NK cells. The Journal of Immunology 129:126.

    PubMed  CAS  Google Scholar 

  11. Kay RG, Mason BH, Stephens EJ, Arthur JF, Hitchcock GG, Trindell PL, Rodgers R, Mel- lins P, 1983. Levamisole in primary breast cancer. A controlled study in conjunction with L-Phenylalanine mustard. Cancer 51:1992–1997.

    CAS  Google Scholar 

  12. Lethinen M, Ahrenberg P, Hanninen A, Ikkala E, Lahtinen R, Levanto A, Palva I, Rajamaki A, Rosengard S, Ruutu T, Sarna S, Selroos O, Timonen T, Waris E, Wasastjerna C, Vilpo J, Vuopio P, 1982. The Finnish leukaemia group: levamisole in maintenance therapy of acute myeloid leukemia in adults. In: G. Mathé, G. Bonnadonna, S. Salmon, Ed., Adjuvant therapies of cancer. Springer-Verlag, Heidelberg, N.Y., p. 70.

    Google Scholar 

  13. Mathé G, 1968. Immunothérapie active de la leucémie L1210 appliquée après la greffe tumorale. Rev. Fr. Et. Clin. Biol., 13:881–883.

    Google Scholar 

  14. Mathé G, Reizenstein P, 1982. La nouvelle immunothérapie des cancers. In: G. Danieli & M. Montromie, Ed. Immunologia. Attualità e prospettive. Pensiero Scientifico, Rome.

    Google Scholar 

  15. Old CJ, Clarke DA, Benacerraf B, 1959. Effect of Bacillus Calmette-Guérin injection on transplanted tumors in the mouse. Nature (London), 184:291.

    Article  Google Scholar 

  16. Olsson L, Mathé G, Reizenstein P, 1984. The biological and immunological response to tumours. In: Clinical Chemotherapy 3; Antineoplastic Chemotherapy (N. Karrer, Ed.) Thieme-Stratton Inc. N.Y.

    Google Scholar 

  17. Omura GA, Vogler WR, Lynn M J, 1977. A controlled clinical trial of chemotherapy versus BCG immunotherapy in remission maintenance of acute myelogenous leukemia. Proc AACR/ASCO 18:272, abstr. C-23.

    Google Scholar 

  18. Omura GA, Vogler WR, Le tante J, 1982. BCG immunotherapy of acute myelogenous leukemia. In: W. Terry, Ed. Immunotherapy of human Cancer. Excerpta Medica, N.Y., p. 3–6.

    Google Scholar 

  19. Reizenstein P, Miale T. Concluding remarks, 1977. In: H Rainer (Ed.). Immunotherapy of acute myeloid leukemia in man. Immunotherapy of malignant diseases. Schattauer, Vienna, p. 441–460.

    Google Scholar 

  20. Reizenstein P, Brenning G, Engstedt L, Franzén S, Gahrton G, Gullbring B, Holm G, Höcker P, Höglund S, Hörasten P, Jameson S, Killander A, Killander D, Klein E, Lantz B, Lindemalm Ch, Lockner O, Lönnqvist B, Mellstedt H, Palmblad J, Pauli C, Skärberg KO, Udén A-M, Vànky F, Wadman B, 1978. Effect of immunotherapy on survival and remission duration in acute non-lymphatic leukemia. In: W Terry, Ed. Progress in Cancer Research and Therapy. Vol. 6. Immunotherapy of Cancer: Present status of trials in man. Raven, N.Y., p. 329–339.

    Google Scholar 

  21. Reizenstein P, Andersson B, Björkholm M, Brenning G, Engstedt L, Gahrton G, Hast R, Holm G, Hörnsten P, Killander A, Lantz B, Lindemalm Ch, Lockner D, Lönnqvist B, Mellstedt H, Palmblad J, Paul C, Simonsson B, Sjögren A-M, Stalfelt A-M, Uden A-M, Wadman B, Oberg G, Ösby E, 1982. BCG plus leukemic cell therapy in patients with acute non-lymphoblastic leukemia: Effect in groups with high and low remission rates. In: W. Terry, Ed. Immunotherapy of Human Cancer. Excerpta Medica, N.Y., p. 17–21.

    Google Scholar 

  22. Reizenstein P, Andersson B, Beran M, 1982. 10. Possible mechanisms of immunotherapy action in acute non-lymphatic leukemia. Macrophage production of colony-stimulating activity. Recent results in cancer research. Springer-Verlag, Berlin-Heidelberg, 80:64–69.

    Google Scholar 

  23. Reizenstein P, 1983. The biological response to disease: Hematologic stress syndrome. Praeger N.Y., 190 p.

    Google Scholar 

  24. Reizenstein P, Mathé G, 1984. Immunomodulating agents. In: Immune Modulation, M.A. Chirigos ed., Ac. Press, N.Y., p. 347–353.

    Google Scholar 

  25. Reizenstein P, Mathé G, 1983. New families of drugs: Biological response modifiers and differentiation inducers. Drugs 26:185–190.

    Google Scholar 

  26. Reizenstein P, Canon C, Mathé G. Biological response to acute leukemia. I Tumor associated antigens and antigen-independent tumor surveillance. In: Clinical and Biological Evaluation of the immunomodifiers. Cancer Treatment Reports, in press.

    Google Scholar 

  27. Reizenstein P, Olsson L, Mathé G, 1983. Immunomodulation and cancer therapy. In: P.K. Ray, Ed. Immunobiology of Transplantation, Cancer and Pregnancy. Pergamon, N.Y., p. 241–253.

    Google Scholar 

  28. Terry W, Rosenberg S (Eds.), 1982. Immunotherapy of human cancer. Excerpta Medica, N.Y.

    Google Scholar 

  29. Urbanitz D, Büchner Th, Pielken H, Van de Loo J. Immunotherapy in the treatment of acute myelogenous leukemia (AML): Rationale, results and future prospects. Klin. Wschr. 61,947(1983).

    Google Scholar 

  30. Vogler WR, Chan YK, 1974. Prolongation of remission in myeloblastic leukemia by Tice strain bacillus Calmette-Guerin (BCG). Lancet 2:128–131.

    Google Scholar 

  31. Vogler R, 1980. Results of randomized trials of immunotherapy for acute leukemia. Cancer Immunol. Immunother. 9:15–21.

    Article  Google Scholar 

  32. Vogler WR, Winton EF, Gordon DS, Jarrel R, Lefante J, Hearn E, 1982. A phase III trial comparing BCG alone, cytosine arabinoside plus daunorubicin, and a combination of BCG, cytosine arabinoside and daunorubicin for maintenance therapy in acute myelogenous leukemia. In: W. Terry, Ed. Immunotherapy of human cancer. Excerpta Medica, N.Y. p. 7–10.

    Google Scholar 

  33. Whittaker JA, Reizenstein P, Callender ST, Cornwell GG, Delamare IW, Gale RP, Gobbi M, Jacobs P, Lantz B, Maiolo AT, Rees JKH, Van Slyck EJ, Vu Van H, 1981. Long survival in acute myelogenous leukemia: an international collaborative study. British Journal of Haematol. 292:1–10

    Google Scholar 

Download references

Authors
  1. P. Reizenstein
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. G. Mathé
    View author publications

    You can also search for this author in PubMed Google Scholar

Editor information

Editors and Affiliations

  1. Medizinische Klinik und Poliklinik der Universität, Albert-Schweitzer-Str. 33, 4400, Münster, Deutschland

    Th. Büchner , D. Urbanitz  & J. van de Loo ,  & 

Rights and permissions

Reprints and permissions

Copyright information

© 1984 Springer: Berlin Heidelberg

About this paper

Cite this paper

Reizenstein, P., Mathé, G. (1984). Biological Response to Acute Leukemia. II. Clinical Effects of Immunomodulation. In: Büchner, T., Urbanitz, D., van de Loo, J. (eds) Therapie der akuten Leukämien. Springer, Berlin, Heidelberg. https://doi.org/10.1007/978-3-642-69934-4_3

Download citation

  • DOI: https://doi.org/10.1007/978-3-642-69934-4_3

  • Publisher Name: Springer, Berlin, Heidelberg

  • Print ISBN: 978-3-540-13682-8

  • Online ISBN: 978-3-642-69934-4

  • eBook Packages: Springer Book Archive

Publish with us

Policies and ethics

Search

Navigation